Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.780
+0.040 (2.30%)
At close: Nov 1, 2024, 4:00 PM
1.740
-0.040 (-2.25%)
After-hours: Nov 1, 2024, 6:59 PM EDT
Heron Therapeutics Employees
Heron Therapeutics had 126 employees as of December 31, 2023. The number of employees decreased by 77 or -37.93% compared to the previous year.
Employees
126
Change (1Y)
-77
Growth (1Y)
-37.93%
Revenue / Employee
$1,082,230
Profits / Employee
-$381,960
Market Cap
269.97M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Accolade | 2,400 |
Sutro Biopharma | 302 |
AVITA Medical | 207 |
Vanda Pharmaceuticals | 203 |
Fate Therapeutics | 181 |
Ocugen | 65 |
Inozyme Pharma | 59 |
Lexeo Therapeutics | 58 |
HRTX News
- 4 days ago - Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 - PRNewsWire
- 23 days ago - Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids - PRNewsWire
- 5 weeks ago - Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") - PRNewsWire
- 2 months ago - Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer - PRNewsWire
- 3 months ago - Heron Therapeutics, Inc., (HRTX) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance - PRNewsWire
- 3 months ago - Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 - PRNewsWire
- 3 months ago - Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System - PRNewsWire